Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events.
Kostine M, Mauric E, Tison A, Barnetche T, Barre A, Nikolski M, Rouxel L, Dutriaux C, Dousset L, Prey S, Beylot-Barry M, Seneschal J, Veillon R, Vergnenegre C, Daste A, Domblides C, Sionneau B, Gross-Goupil M, Ravaud A, Forcade E, Schaeverbeke T; FHU ACRONIM.
Kostine M, et al. Among authors: sionneau b.
Eur J Cancer. 2021 Nov;157:474-484. doi: 10.1016/j.ejca.2021.08.036. Epub 2021 Oct 11.
Eur J Cancer. 2021.
PMID: 34649118
Free article.